— Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019, vs. $0.74 per share loss expected.
— Research and development expenses decreased to $1.4 million from $2.3 million last year
— General and administrative expenses were $0.9 million during the three-month period, up 29% from last year
— Recorded cash of $15.4 million as of September 30, 2019, compared to $1.0 million at December 31, 2018
— Net cash used in operating activities was $6.1 million during the nine-month period ended September, compared to $4.8 million last year
— Recently, appointed Martina Molsbergen, chief executive officer of C14 Consulting, to the board of directors of Bio-Path
Most Popular
Key highlights from Eli Lilly’s (LLY) Q1 2024 earnings results
Eli Lilly and Company (NYSE: LLY) reported first quarter 2024 earnings results today. Worldwide revenue was $8.77 billion, up 26% from the year-ago quarter, driven by increases of 16% in
MCD Earnings: Key quarterly highlights from McDonald’s Q1 2024 financial results
McDonald's Corporation (NYSE: MCD) reported first quarter 2024 earnings results today. Revenues increased 5% year-over-year to $6.1 billion. Revenue growth was 4% in constant currencies. Net income grew 7% to
KO Earnings: All you need to know about Coca-Cola’s Q1 2024 earnings results
The Coca-Cola Company (NYSE: KO) reported its first quarter 2024 earnings results today. Net revenues grew 3% year-over-year to $11.3 billion. Organic revenues grew 11%. Net income attributable to shareowners
